LINC02231: A Potential Drug Target Or Biomarker (G109729131)

Target Name: LINC02231

NCBI ID: G109729131

LINC02231

Other Name(s): Long intergenic non-protein coding RNA 2231 | long intergenic non-protein coding RNA 2231 | RP11-766N7.4

LINC02231: A Potential Drug Target Or Biomarker

LINC02231 is a non-protein coding RNA (ncRNA) that has been identified by bioinformatic analysis as having potential drug targets or biomarkers. The RNA sequence of LINC02231 is similar to that of known microRNA (miRNA) sequences, which are small non-coding RNAs that play a critical role in post-transcriptional gene regulation.

MicroRNAs are highly conserved, non-coding RNAs that are derived from RNA-protein interactions. They are typically processed by the 20-endonuclease enzyme, which leads to a loss of the 5' end and the formation of a small RNA molecule with a single base extension. This loss of the 5' end is important for the stability and localization of microRNAs, as well as their ability to interact with their target proteins.

LINC02231 is a non-protein coding RNA that has a sequence similar to known miRNA sequences.

The identification of LINC02231 as a potential drug target or biomarker is based on several factors. First, the conservation of its sequence with known miRNA sequences suggests that it may have similar functional characteristics. Second, the fact that LINC02231 is a non-protein coding RNA also suggests that it may not be a protein target, which is often the case for known miRNA targets. Finally, the identification of LINC02231 as a potential drug target or biomarker is consistent with recent studies that have used microRNA-based approaches to identify potential therapeutic targets in diseases such as cancer, neurodegenerative diseases, and cardiovascular disease.

In addition to its potential drug target or biomarker status, LINC02231 also has potential as a therapeutic target due to its role in cell signaling. The RNA has been shown to regulate the activity of several cellular signaling pathways, including the TGF-β pathway, the Wnt pathway, and the Hedgehog pathway. These pathways are involved in a variety of cellular processes, including cell growth, differentiation, and survival.

Furthermore, LINC02231 has been shown to play a role in the regulation of gene expression in cancer cells. Several studies have shown that LINC02231 is downregulated in various types of cancer, and that this downregulation is associated with cancer cell survival and progression. Therefore, LINC02231 may be a promising target for cancer therapies.

In conclusion, the potential drug target or biomarker status of LINC02231 as a non-protein coding RNA that is similar to known miRNA sequences and has been shown to regulate multiple cellular signaling pathways and play a role in the regulation of gene expression in cancer cells makes it a promising target for further research. Further studies are needed to determine the full extent of LINC02231's potential as a drug target or biomarker, as well as its efficacy in clinical trials.

Protein Name: Long Intergenic Non-protein Coding RNA 2231

The "LINC02231 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02231 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets